HC Wainwright Comments on Kura Oncology Q2 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Kura Oncology in a research note issued on Thursday, February 27th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Kura Oncology’s FY2025 earnings at ($3.14) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.24) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($1.12) EPS.

KURA has been the subject of several other reports. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Price Performance

Kura Oncology stock opened at $7.33 on Monday. The firm has a market capitalization of $570.01 million, a P/E ratio of -3.11 and a beta of 0.85. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The business has a 50-day moving average of $8.10 and a 200-day moving average of $13.64. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Suvretta Capital Management LLC raised its stake in shares of Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock worth $41,973,000 after acquiring an additional 615,211 shares during the last quarter. RA Capital Management L.P. acquired a new position in shares of Kura Oncology during the 4th quarter worth approximately $38,769,000. Millennium Management LLC increased its holdings in shares of Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock worth $20,618,000 after acquiring an additional 1,521,954 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.